Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (370)	10/21/1998 8:43:00 PM
From: Bull-like	Read Replies (4) \| Respond to of 642

Anthony, I think these studies will have profound impact on the prevention of breast-cancer as well as on the bottom-line of LLY. Who knows, Evista may become a Cinderella story in the aging baby-boomers in the next century. This is probably just a start. I am really encouraged by lly's decision to increase spending on R&D even in this turbulent market. Da bull

To: Anthony Wong who wrote (370)	10/21/1998 9:32:00 PM
From: Anthony Wong	Respond to of 642

10/21 11:14 Danish shares fall on profit-taking, Novo<NVOb.CO> COPENHAGEN, Oct 21 (Reuters) - Danish shares fell on Wednesday in thin trade marked by profit-taking, and with bio-tech blue-chip Novo Nordisk dented by a sales advance of rival Eli Lilly<LLY.N> in Novo's main markets, dealers said. The KFX top-20 index shed 1.50 points or 0.75 percent to 197.18 in modest 520 million crown turnover. The KFX November future fell 3.00 points to 198.00. Novo Nordisk fell 18 crowns to 700. Eli Lilly posted 19 percent higher Q3 sales with insulin sales outside the United States up 18 percent. This was bad news for Novo as it implied that the Danish company had lost market share, dealers said.